EUCTR2014-005330-58-NL进行中（未招募）1 期
A phase I/II open label clinical trial assessing safety and efficacy of intravesical instillation of VPM1002BC in patients with recurrent non-muscle invasive bladder cancer after standard BCG therapy
SAKK (Schweizerische Arbeitsgemeinschaft für klinische Krebsforschung)0 个研究点目标入组 39 人开始时间: 2016年8月15日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 39
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Disease characteristics:
- •-Histologically confirmed diagnosis of recurrent NMIBC (urothelial carcinoma) including repeat TURB confirming tumor-free state of the bladder (confirmed by TURB and biopsy) For patients with pure CIS of the bladder no repeat TURB is necessary.
- •-Negative cytology before start of treatment, except for patients with concomitant CIS.
- •-Planned treatment starts 2-6 weeks after last TURB
- •-Pathological grading includes reporting according to WHO 1973 and 2004.
- •-One previous cycle of intravesical BCG (induction phase with at least 5 instillations ± maintenance) not more than 5 years ago for NMIBC.
- •-Patients have recurrent high-risk NMIBC for progression (score 7-23), based on the European Organization for Research and Treatment of Cancer scoring system, failing BCG therapy (EAU 2008 definition), for whom radical cystectomy or re-induction with standard BCG is indicated. This includes:
- •o Patients with high-grade, non-muscle invasive tumor(s) present at both 3 and 6 months after start of the previous cycle of BCG therapy, and
- •o Any worsening of the disease under BCG treatment, such as a higher number of recurrences, higher tumor category or higher grade, or appearance of CIS, including low grade tumors, in spite of an initial response.
- •Patient characteristics:
- •-Patient must give written informed consent before registration.
- •-Baseline Quality of Life questionnaire has been completed.
- •-WHO performance status 0-2
- •-Age 18 - 85 years
- •-Adequate hematological values: WBC =2.5 x 109/L, platelets = 100 x 109/L
- •-Adequate hepatic function: total bilirubin = 2 x ULN, AST/ALT = 5 x ULN
- •-Adequate renal function: eGFR = 30 mL/min/1.73m2, no need for dialysis
- •-Women are not breastfeeding. Sexually active women must ensure that their partner wears a condom during intercourse. Women with child-bearing potential are using effective contraception, are not pregnant and agree not to become pregnant during participation in the trial and during the 6 months thereafter. A negative pregnancy test (serum or urine) before inclusion (within 7 days) into the trial is required for all women with child-bearing potential.
- •Sexually active men must use a condom during intercourse and ensure that his partner practices contraception. Men agree not to father a child during participation in the trial and during 6 months thereafter.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 14
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 25
排除标准
- •Disease characteristics:
- •-Current or previous = T2 urothelial carcinoma (UC) of the urinary bladder
- •-Concomitant UC of upper urinary tract, prostate or urethra*, small cell carcinoma of the bladder (with or without neuroendocrine differentiation), micropapillary urothelial carcinoma, pure squamous cell carcinoma of the bladder, (UC with squamous differentiation is allowed), pure adenocarcinoma, lympho-vascular invasion (LVI) in the TURB specimen. * If a staged transurethral resection of the prostate (TURP) shows no histological evidence of UC in the deep resection layer of the prostate, the patient can be included.
- •-Previous or current evidence of UC in a bladder diverticulum
- •-Evidence of metastatic disease in the (thoraco-)abdominal CT scan at registration
- •-Bladder surgery or traumatic catheterization or TURB within 2 weeks prior to the expected start of trial treatment
- •-Administration of systemic cytotoxic agents within the past 3 years or administration of repeated cytostatic/cytotoxic drugs by intravesical instillations after a UC recurrence after the first BCG therapy (during the past 5 years). Exceptions are one immediate intravesical instillation (<24h) of a cytostatic/cytotoxic drug after TURB or repeated cytostatic/cytotoxic drugs by intravesical instillations before the first BCG therapy.
- •Patient characteristics:
- •-Stress urinary incontinence >I°, severe urge or urge urinary incontinence preventing the patient to keep the IMP in the bladder for at least 1 hour (anticholinergics and blocked catheter are allowed in order to achieve this criterion)
- •-Residual urinary bladder volume after micturition (measured by ultrasound of bladder or inserted catheter) is > 150 ml.
- •-Bladder diverticula or any other anatomical anomalies of the bladder that cannot be assessed by cystoscopy
- •-Active concomitant malignant conditions except basal cell skin carcinoma and cervical carcinoma in situ. History of malignancy in the last 3 years except previous NMIBC.
- •-Primary or secondary immunodeficiencies
- •-Positive HIV test
- •-Chronic administration (defined as more than 14 consecutive days) of immunosuppressive drugs or other immune modifying drugs within three months before instillation (for corticosteroids, this will mean prednisolone, or equivalent, 10mg/day). Inhaled and topical steroids are allowed.
- •-Uncontrollable urinary tract infection, macroscopic haematuria, suspicion of bladder perforation, urethral strictures (if interfering with trial procedures)
- •-Current and past pelvic radiation and brachytherapy
- •-Active tuberculosis, suspicion of active tuberculosis, other ongoing mycobacterial infection.
- •-Severe or uncontrolled cardiovascular disease (congestive heart failure NYHA III or IV, unstable angina pectoris, history of myocardial infarction within the last three months, significant arrhythmias, significant QT-prolongation).
- •-History of anaphylaxis or severe allergic reactions, known allergies to any component of the investigational product, BCG intolerance
- •-Local and severe allergy (e.g. ulceration, systemic reactions) to PPD test
研究者
相似试验
进行中（未招募）
1 期
To evaluate the safety and tolerability of Cytokine cocktail therapy in healthy volunteers from healthy donorsCTRI/2020/05/025432Health Care Global HCG Cancer CentreInternational stemcell services ltd
已完成
不适用
A phase I open-label clinical trial, evaluating the therapeutic vaccine hVEGF26-104/RFASE in patients with advanced solid tumorsadvanced cancerAdvanced solid tumor10027655NL-OMON47883Vrije Universiteit Medisch Centrum27
已完成
不适用
A phase I-II open label clinical trial, evaluating the efficacy and safety of administration of the therapeutic vaccine PEP-223/CoVaccine HT, to hormone treatment naive, immunocompetent subjects with T1-3, N0-1/x, M0 prostate cancer, eligible for hormone therapy.prostate cancerNL-OMON35662Pepscan Therapeutics B.V.12
进行中（未招募）
1 期
A phase I-IIa clinical trial, evaluating the therapeutic vaccine hVEGF26-104/RFASE in patients with advanced cancerAdvanced solid tumorsMedDRA version: 16.0Level: LLTClassification code 10048683Term: Advanced cancerSystem Organ Class: 100000004864EUCTR2013-002663-25-NLVU University Medical Center27
已完成
1 期
A Clinical study on quadrivalent Human Papilloma virus vaccineCTRI/2017/02/007785Serum Institute of India Pvt Ltd47